Selumetinib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Selumetinib and local guidelines before prescribing.

MEK inhibitor

Mechanism

MEK inhibitor.

Uses

Symptomatic plexiform neurofibromas in NF1 children.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Diarrhoea, rash, raised CK, cardiomyopathy.

Interactions

CYP3A4 interactions.

Contraindications and cautions

Hepatic impairment

Monitoring

LVEF, CK

Pregnancy and breastfeeding

Contraindicated

Renal and hepatic impairment

Avoid in moderate to severe hepatic impairment

Overdose and reversal

Supportive

Special advice

LVEF monitoring.

More from the textbook: uses, cautions and other points
Where it is discussed in the book